RBC
MIRM icon

Roble Belko & Company’s Mirum Pharmaceuticals MIRM Stock Holding History

Roble Belko & Company’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19
Closed -$2K – 470
2026
Q1 		$2K Hold
19
– – ﹤0.01% 394
2025
Q4 		$2K Hold
19
– – ﹤0.01% 391
2025
Q3 		$1K Hold
19
– – ﹤0.01% 400
2025
Q2 		$1K Hold
19
– – ﹤0.01% 383
2025
Q1 		$1K Hold
19
– – ﹤0.01% 370
2024
Q4 		$1K Buy
+19
New +$792 ﹤0.01% 345

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Roble Belko & Company's MIRM Position: Q2 2026 in Review

Roble Belko & Company sold out of Mirum Pharmaceuticals (MIRM) in Q2 2026, closing a stake of 19 shares — an estimated $2K sold.

Roble Belko & Company first reported a position in MIRM in Q4 2024 and held it in 6 quarters. The position peaked at $2K in Q1 2026. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Roble Belko & Company reported no remaining Mirum Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Roble Belko & Company sold 19 Mirum Pharmaceuticals shares in Q2 2026, an estimated $2K.
  • Roble Belko & Company first reported a position in Mirum Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • Roble Belko & Company's Mirum Pharmaceuticals position peaked at $2K in Q1 2026.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Roble Belko & Company's 13F filing for Q2 2026, filed 24 Jul 2026.